Val(659)-->Glu mutation within the transmembrane domain of ErbB-2: effects measured by (2)H NMR in fluid phospholipid

S Sharpe1, K R Barber, C W Grant

  • 1Department of Biochemistry, University of Western Ontario, London, Canada.

Biochemistry
|June 1, 2000
PubMed

Insights

The Val659Glu mutation in ErbB-2 transmembrane domain alters helix structure, affecting receptor dimerization and oncogenic transformation. This study reveals intramolecular rearrangements in the mutant transmembrane helix.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Structural Biology

Background:

  • Point mutations in receptor tyrosine kinase transmembrane domains, like Val->Glu in ErbB-2, are linked to oncogenic transformation.
  • The Val659Glu substitution in ErbB-2 is hypothesized to promote cancer by altering transmembrane domain associations.

Purpose of the Study:

  • To investigate the structural basis of the oncogenic Val659Glu mutation in the ErbB-2 transmembrane domain.
  • To analyze how this mutation affects peptide associations within fluid bilayer membranes.

Main Methods:

  • Produced wild-type and mutant ErbB-2 transmembrane peptides (50-mers) with deuterium probes.
  • Utilized SDS-PAGE, Circular Dichroism (CD) spectroscopy, and 2H Nuclear Magnetic Resonance (NMR) in phospholipid bilayers.
  • Employed site-directed mutagenesis to confirm spectral assignments and probe locations.

Main Results:

  • Peptides existed as monomers in equilibrium with dimers/oligomers; CD spectra indicated alpha-helical structures.
  • 2H NMR revealed the mutant's Glu659 is uncharged at neutral pH and induces significant side chain angulation changes (6-8 degrees) at Ala657 and downstream residues.
  • The mutation caused intramolecular rearrangements in the transmembrane helix, affecting potential lateral associations, while wild-type showed greater backbone flexibility.

Conclusions:

  • The Val659Glu mutation induces substantial intramolecular structural changes within the ErbB-2 transmembrane helix.
  • These rearrangements likely influence receptor dimerization and contribute to the oncogenic potential of ErbB-2.
  • The study provides structural insights into how transmembrane domain mutations drive receptor tyrosine kinase-associated cancers.